L1CAM is a promotor for tumor invasion, whereas inhibition of L1CAM can suppress breast cancer aggressiveness and attenuate cisplatin resistance via modulating AKT signaling (Li et al., 2022; Zhang, Shen & Guo, 2022b). Here, AKT1 is linked to breast carcinoma.